Purpura fulminans as a sequel to erythema nodosum in a child with homozygous Leiden mutation and acquired protein S deficiency

Acta Paediatrica, International Journal of Paediatrics

Volumn 94, Issue 8, 2005, Pages 1155-1158

  Bruun, Cathrine Foyn ^a,b   Langbakk, Bodil ^b   Steigen, Sonja Eriksson ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

APC R; Erythema; Leiden; Nodosum; Purpura

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; IBUPROFEN; PENICILLIN G; PREDNISOLONE; PROTEIN S; WARFARIN;

ANAMNESIS; ARTERY COMPRESSION; ARTICLE; BLOOD CULTURE; CASE REPORT; CLINICAL EXAMINATION; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHEMA NODOSUM; FEVER; FULMINATING PURPURA; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HOMOZYGOSITY; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LEG EDEMA; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN S DEFICIENCY;

BIOPSY, NEEDLE; CHILD; COMBINED MODALITY THERAPY; ERYTHEMA NODOSUM; FACTOR V; FOLLOW-UP STUDIES; HEPARIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PLASMA EXCHANGE; POINT MUTATION; PREDNISOLONE; PROTEIN S DEFICIENCY; PURPURA, SCHOENLEIN-HENOCH; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WARFARIN;

EID: 23844539410     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250510025743     Document Type: Article

References (10)

1. Brodell RT, Mehrabi D. Underlying causes of erythema nodosum: Lesions may provide clue to systemic disease. Postgrad Med 2000;108:147-9.
2. Kakourou T, Drosatou P, Psychou F, Aroni K, Nicolaidou P. Erythema nodosum in children: a prospective study. J Am Acad Dematol 2001;44:17-21.
3. Levin M, Eley B, Louis J, Cohen H, Young L, Heyderman R. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 1995;127:355-63.
4. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995;77:1-43.
5. Product Range, Chromogenix, March 2000, Chromogenix Instrumentation Laboratory SpA, Milano, Italy.
6. Haemostasis Brochure Cat. No. 27865, Jan 2000, Diagnostica Stago, Asnieres-sur-Seine, France.
7. Cadroy Y, Sie P, Alhenc-Glas M, Aiach M. Evaluation of APC-R in the plasma of patients with Q506 mutation of Factor V (Factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995;73:734-5.
8. Naschitz JE, Yeshurun D, Shajrawi I, Misselevich I, Boss JH. The Phlebopathies of the Fasciitis Panniculitis Syndrome. Scand J Rheumatol 1992;21:24-7.
9. Gurgey A. Clinical manifestations in thrombotic children with factor V Leiden mutation. Ped Hem Oncol 1999;16:233-7.
10. Sackesen C, Secmeer G II, Gurgey A, Kanra G, Ecevit Z, Ceyhan M, et al. Homozygous Factor V Leiden mutation in a child with meningococcal purpura fulminans. Ped Inf Dis J 1998;17:87.